Abstract
Malignant gliomas are optimally managed with maximal surgical resection followed by radiation and chemotherapy. Drug delivery challenges and chemoresistance limits the efficacy of standard chemotherapeutic agents. Understanding glioma biology has led to the development of a variety newer molecular targeting agents which have begun to show exciting preliminary results. Bevacizumab (Avastin) is one such drug likely to play a key role in malignant glioma therapy. We review the current literature in regard to the use of bevacizumab and its adverse effects in neurosurgical patients.
Related Journals
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents